Urteste S.A. URT
GPW · Poland · Health Technology
PLN 42.20+0.20 (+0.48%)
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Urteste S.A. Receives U.S. Patent for the Panuri Test Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has received a patent from the United States Patent and Trademark Office (USPTO) for an invention developed as part of the Panuri project - “Diagnostic marker for pancreatic cancer.” Panuri, developed as a non-invasive test for detecting pancreatic cancer, is Urteste’s most a
Urteste S.A. enrolls the first patient in the Panuri test clinical study Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the Panuri test for the detection of pancreatic cancer. The company expects to receive the results of the interim analysis in the fourth quarter of this year. The study is proceeding according to sched
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.